Search research articles
Contact Us
Filters
Showing results (181-190 of 231) with videos related to
Page
of 24
Sort By:
The Lancet. Oncology
|
November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
The Lancet. Oncology
|
May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Albiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
Cancer
|
February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
Do-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Amita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2021
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, et al.
The Lancet. Respiratory Medicine
|
December 19, 2017
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Chia-Chi Lin, Jin-Yuan Shih, Chong-Jen Yu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
Solange Peters, Alice T Shaw, Benjamin Besse, et al.
JTO Clinical and Research Reports
|
October 10, 2025
Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study
Byoung Chul Cho, Myung-Ju Ahn, Makoto Nishio, et al.
Investigational New Drugs
|
November 26, 2013
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
Sharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.
Page
of 24
Search research articles
Search
Showing results (181-190 of 231) with videos related to
Sort By:
Page
of 24
The Lancet. Oncology
|
November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial
Alice T Shaw, Benjamin J Solomon, Rita Chiari, et al.
The Lancet. Oncology
|
May 10, 2016
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro, Hyun Cheol Chung, Veena Shankaran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2021
Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study
Albiruni R Abdul Razak, Sebastian Bauer, Cristina Suarez, et al.
Cancer
|
February 7, 2023
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
Do-Youn Oh, Alain Algazi, Jaume Capdevila, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 24, 2020
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
Amita Patnaik, Timothy A Yap, Hyun Cheol Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2021
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, et al.
The Lancet. Respiratory Medicine
|
December 19, 2017
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Chia-Chi Lin, Jin-Yuan Shih, Chong-Jen Yu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 29, 2020
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
Solange Peters, Alice T Shaw, Benjamin Besse, et al.
JTO Clinical and Research Reports
|
October 10, 2025
Durvalumab With or Without Tremelimumab in Combination With Chemoradiotherapy in Patients With Limited-Stage SCLC: Results from the Phase 1 CLOVER Study
Byoung Chul Cho, Myung-Ju Ahn, Makoto Nishio, et al.
Investigational New Drugs
|
November 26, 2013
A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors
Sharad Ghamande, Chia-Chi Lin, Daniel C Cho, et al.
Page
of 24